The 42-kDa angiogenin binding protein isolated previously has been purified to electrophoretic homogeneity. It has been identified as a member of the actin family by peptide mapping and partial amino acid sequencing. The interaction of bovine muscle actin with angiogenin is similar to that of the angiogenin binding protein. Angiogenin induces the polymerization of actin below the critical concentration for spontaneous polymerization. The interaction occurs both in solution and on a poly(vinylidene difluoride) membrane. It is inhibited by excess unlabeled angiogenin and also by platelet factor 4 and protamine, which are known inhibitors of angiogenesis. Two other angiogenic molecules, basic fibroblast growth factor and tumor necrosis factor a, bind to 125I-labeled actin and can be crosslinked by a water-soluble carbodilmide. Both actin and an anti-actin antibody inhibit the angiogenic activity of angiogenin in the chicken embryo chorioallantoic membrane assay. The results indicate that the angiogenin binding protein is a cell surface actin and suggest that the reaction between angiogenin and this actin is an essential step in the angiogenesis process induced by angiogenin.
Angiogenin is a 14-kDa protein purified initially from serumfree supernatants of an established human adenocarcinoma cell line, HT-29 (1) . It was the first human tumor-derived angiogenic protein to be isolated based on its in vivo activity. It stimulates endothelial cells to produce diacylglycerol (2) and secrete prostacyclin (3) by phospholipase activation. It supports endothelial and fibroblast cell adhesion (4) and modulates a mitogenic effect in certain cells (5) . An angiogenin binding protein (AngBP), which has properties consistent with its being a component of a cellular receptor for angiogenin, has been identified and isolated from a transformed endothelial cell line, GM7373 (6) . It is a cell-surface protein with an apparent molecular mass of 42 kDa and is released from endothelial cells by exposure to heparnn, heparan sulfate, or angiogenin itself.
We report here the further purification and characterization of AngBP. Tryptic peptide mapping and amino acid sequence analysis indicate that AngBP is a member of the actin family. The binding of angiogenin to bovine muscle actin and the inhibitory effect of actin and anti-actin antibodies on angiogenin-induced neovascularization on the chicken embryo chorioallantoic membrane (CAM) are also reported. The mechanism by which AngBP is released from the cell surface and the physiological significance of its presence and displacement remain to be elucidated.
MATERIALS AND METHODS
Materials. Bovine angiogenin, purified by the method of Bond and Vallee (7) , was provided by R. Shapiro. 125I-labeled angiogenin and 1251-labeled actin of specific activities 25 ,uCi/,ug and 10 ,Ci/,g, respectively ( 1 Ci = 37 GBq), were prepared with Enzymobeads (Bio-Rad). CNBr-activated Sepharose 6MB was from Pharmacia; bovine (A3653) and porcine (A0541) muscle actin, platelet factor 4 (PF-4), and protamine were from Sigma; basic fibroblast growth factor (bFGF), tumor necrosis factor a (TNF-a), and transforming growth factor ( (TGF-,B) were from Genzyme; Na125I was from DuPont/New England Nuclear; and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide was from Pierce. A polyclonal rabbit anti-actin antiserum (A2668) was purchased from Sigma. Its IgG fraction was prepared by protein A-Sepharose chromatography. Normal rabbit IgG was prepared similarly.
Isolation of AngBP. GM7373 cells (8) were cultured and used to prepare AngBP as described (6) .
Binding Affinity chromatography. An 8 x 20 mm column of angiogenin-Sepharose on which angiogenin (0.5-1 mg) was immobilized (6) was equilibrated with PBS, and 1 ml of actin (0.2 mg/ml) in the same buffer was applied at a flow rate of 20 ml/hr. Bound actin was subjected to the same procedure of washing and elution as described above for the purification of AngBP.
Membrane blotting. Actin was separated either by SDS/ PAGE or by two-dimensional electrophoresis and electrotransferred onto a poly(vinylidene difluoride) microporous membrane. The membrane was blocked by overnight agitation at 4°C in rinse buffer (10 mM Tris'HCl, pH 7.5/150 mM NaCl/1 mM EDTA/0.02% Triton X-100) containing 5% (wt/vol) bovine serum albumin. The membrane was then incubated with 125I-labeled angiogenin (106 cpm/ml) in rinse buffer containing 0.3% bovine serum albumin at 4°C overnight with shaking. After three washes in the rinse buffer, the membrane was air-dried and subjected to autoradiography.
Biological Assay. Angiogenesis was measured on the CAM by the method ofKnighton et al. (9) as described (1) . Potential inhibitors were mixed with angiogenin 15 min prior to application onto the discs. RESULTS Purification of AngBP. AngBP was purified to electrophoretic homogeneity by the procedures described above. HPLC Abbreviations: AngBP, angiogenin binding protein; CAM, chorioallantoic membrane; bFGF, basic fibroblast growth factor; TNF-a, tumor necrosis factor a; PF-4, platelet factor 4; TGF-13, transforming growth factor ,B.
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(C4 column) of the eluate from the angiogenin-Sepharose column gave four major peaks with retention times of 27, 31, 35 and 40 min (Fig. 1) (10) . No difference in sequence from known actins was apparent. Table 1 lists a typical amino acid analysis of C4-purified AngBP. It is close to that obtained for a sample of bovine skeletal muscle actin except for the high leucine/isoleucine ratio and the low tyrosine and methionine content. The actual composition of bovine skeletal muscle actin, based on its primary structure, is also shown. The composition of AngBP is even closer to that for bovine brain capillary actin (Table 1) , which differs substantially in tyrosine and leucine content (11) . Bovine smooth muscle actin composition is also listed for comparison.
Binding of Angiogenin to Actin. The binding of 125I-labeled angiogenin to either bovine or porcine muscle actin was investigated by crosslinking followed by gel electrophoresis. (6) .
The binding of actin to angiogenin-Sepharose was carried out under the same conditions used for purification ofAngBP by affinity chromatography. As judged by SDS/PAGE and protein staining, >90% of the applied actin binds to the column (data not shown). Actin also bound to the affinity column when equilibrated with actin depolymerization buffer. Bound actin could only be eluted by 3% SDS containing 0.5% 2-mercaptoethanol. The angiogenin-actin complex could not be dissociated by 3 M NaCl or H20.
Binding of 125I-labeled angiogenin to actin was also analyzed by ligand blotting. 125I-labeled angiogenin was found to bind to membrane-immobilized actin (data not shown).
Polymerization of Actin by Angiogenin. Many actin-binding proteins either promote or inhibit actin polymerization (12) . Hence the effect of angiogenin on actin polymerization was examined. When angiogenin is mixed with globular actin at 0.2 mg/ml in depolymerization buffer, which is below the critical concentration of actin for spontaneous polymerization (0.5 mg/ml), visible turbidity develops within seconds due to the formation of aggregates. The aggregates sediment readily on microcentrifugation, stain strongly with BODIPY FL phallacidin (Molecular Probes), exhibit a needle-like structure under light microscopy (data not shown), and resolve into two bands corresponding to actin and angiogenin on SDS/PAGE (Fig. 4) .
The catalytically inactive angiogenin mutants H13A and H114A (13) (6) .
PF-4 and Protamine Inhibit Angiogenin Binding to Actin. Two known angiogenesis inhibitors, PF-4 and protamine, were examined for their effect on angiogenin binding to actin (Fig. 5) . The crosslinking of 125I-labeled angiogenin and actin was completely inhibited by the presence of PF-4 (0.4 .g/ml) or protamine (10 pg/ml), respectively.
1I25-Labeled Actin Binds Other Angioge Factors. The
observations that angiogenin binds to actin and that PF-4 and protamine inhibit the binding raise the question of whether binding to actin is characteristic of angiogenic molecules. To examine this possibility, direct binding and crosslinking experiments of 125I-labeled actin to bFGF, TNF-a, and TGF-, were performed. Fig. 6 shows that 125I-labeled actin is able to bind to and form complexes with bFGF and TNF-a, as established by crosslinking. 125I-labeled actin does not crosslink with TGF-,t under the conditions described.
Actin Inhibits the Biological Activity of Angiogenin. The ability of actin to inhibit angiogenin's biological activity was assessed by the chicken CAM assay (Table 2 ). In five sets of assays, 10 ng of angiogenin alone induced a positive response in 48% of the eggs (P = 0.00003), consistent with its doseresponse results in previous studies (1) . In the presence of 300 ng of actin, the activity of this much angiogenin was reduced to 36%, which is a statistically significant (P = 0.012) positive response. With a 100-fold molar excess of actin (3 pg), however, the effect of angiogenin in this assay was completely abolished (P = 0.196). Actin alone at either concentration did not induce significant angiogenesis. Anti-Actin Antibody Inhibits the Biological Activity of Angiogenin. The involvement of actin in the induction of angiogenesis by angiogenin was tested by determining whether anti-actin antibodies interfere with this process. Indeed, a 10-fold molar excess of an anti-actin antibody inhibits (P = 0.29) the angiogenesis induced by 10 ng of angiogenin ( (15) , suggesting that there may be a functional basis for the actin isoform multiplicity although the sequences are remarkably conserved (10, 15) .
Amino acid composition, tryptic peptide mapping, and sequence analysis indicate that AngBP is a member of the actin family. Indeed, its composition is closely similar to that of the most abundant protein in bovine brain microvessels, which was also identified as a form of actin by the same techniques. This latter protein was localized to the plasma membrane of the capillary endothelial cells by immunohistochemical staining (11) . The differences in amino acid composition between AngBP and any of the bovine actins (Table  1 ) are minor and most that have been noted may be associated with the conditions for acid hydrolysis. The close similarity of the actin and AngBP peptide maps (Fig. 2) suggests a correspondingly close similarity in sequence. Thus, it remains to be established whether or not AngBP represents another form of actin or is identical to one already characterized. We had reported (6) that AngBP is a cell surface protein that can be detached from the cell by heparan sulfate and, probably, by angiogenin. Immunofluorescent staining of cultured endothelial cells with anti-actin antibodies reveals the presence of a smooth muscle type of a-actin on the cell surface (J. Moroianu, J.W.F., J.F.R., and B.L.V., unpublished data). Exposure of the cells to angiogenin diminishes the cell surface staining with anti-actin antibodies, supporting the conclusion that AngBP is a dissociable cell surface actin. We cannot exclude the possibility, of course, that angiogenin also reacts with actin intracellularly.
Actin has been reported to be present on the surface of normal B lymphocytes (16, 17) and to be a constituent of the intercellular matrix of smooth muscle (18) , fibroblasts (19) , and endothelial cells (20) . Furthermore, it is distributed along the vascular internal elastic membrane in small arterioles and capillaries as shown by immunohistological staining (21) . The present data provide further clues for understanding the physiological significance of cell surface actins.
Angiogenin induces the polymerization of actin. This has precluded direct measurements of binding by standard spectral or fluorescent means. Nevertheless, it may relate to the physiological mode of actin of angiogenin. We have reported (6) that AngBP (actin) appears to be released from the cell surface of cultured endothelial cells by addition of angiogenin to the medium. Indeed, it might be that induction of polymerization on binding of angiogenin to cell surface AngBP causes it to detach from the cell surface. Cell surface actin of cultured endothelial cells likely corresponds to extracellular matrix (ECM)-actin in vivo. Hence, binding of angiogenin to ECM-actin molecules could lead to cell detachment from the ECM followed by migration, proliferation, and differentiation into microvessels, all of which are components of the angiogenic process. Importantly, reorganization of extracellular actin has been observed during the growth and formation of the corneal endothelium (22) .
Angiogenin is a member of the ribonuclease superfamily with 33% sequence identity to bovine pancreatic RNase A and an overall sequence similarity of -53%. All of the major components of the active site of RNase A are conserved and angiogenin exhibits ribonucleolytic activity, which although greatly diminished compared to that of RNase A, is nevertheless essential to its angiogenic activity. In addition the nonactive site region of angiogenin that encompasses residues 60-68 has been implicated as part of a cell surface receptor binding site that is also crucial for angiogenic activity (14) . This region is relatively well conserved among the angiogenins from various species but differs markedly from the pancreatic RNases. It is notable that none of these RNases is angiogenic and only bovine seminal RNase, a dimeric protein with a number of unusual biological properties, has been reported to be an actin-binding protein, a property that is lost on monomerization (23) .
The modified angiogenins Ang-K and Ang-E, whose putative cell-surface binding sites have been disrupted by 1220 Biochemistry: Hu et al.
limited proteolysis (14) , are much weaker inducers of the polymerization of actin than native angiogenin or the catalytic active site mutant angiogenins H13A and H114A. This suggests that the binding of angiogenin to actin involves its cell surface binding region and is consistent with the proposed dual site model for angiogenin (14) .
A large number of proteins can bind to actin and function in the nucleating, capping, stabilizing, severing, bundling, and mechanical movement of actin filaments (12) . Through the interactions with these proteins, actin filaments participate in several essential cellular functions, including cell motility, cytokinesis, maintenance of cell structure, and organelle movement (12) . Angiogenin can be added to the growing list of actin binding proteins. One of the earliest changes in the cytoskeleton after certain ligands bind to their receptors is the polymerization of globular actin to form filamentous actin (24) . An indirect association between receptor binding and rapid polymerization of actin has been demonstrated in several receptor systems on various cell types (25) . A direct reaction between angiogenin and actin could be more effective. Castellani and O'Brien (26) reported that the biologically active form of nerve growth factor interacts with actin, which becomes organized into wellordered paracrystalline arrays. They suggested that the in vitro formation of nerve growth factor-actin complexes may be related to the in vivo mechanism of action of nerve growth factor.
The crosslinking of angiogenin to actin is inhibited by protamine, a 4.3-kDa arginine-rich basic protein known for its capacity to inhibit in vivo angiogenesis induced by various angiogenic stimuli (embryologic, neoplastic, inflammatory, and immunogenic) (27) . Another angiogenesis inhibitor, , also inhibits the crosslinking of angiogenin to actin. The finding that in vivo angiogenesis inhibitors can antagonize ligand-receptor (or ligand-binding protein) interactions is important and implies that the binding of angiogenin to actin may have physiological significance.
It is not clear as yet whether actin is the functional receptor that is responsible for the cellular responses to angiogenin observed in cultured endothelial and smooth muscle cells (2) (3) (4) (5) and for the in vivo neovascularization induced by angiogenin. However, the data suggest that the binding of angiogenin to actin may be an essential step. In particular the inhibitory effect of actin and anti-actin antibodies on angiogenin-induced angiogenesis in the CAM assay support this hypothesis. It cannot be ruled out that this inhibition has a more complex basis including but not solely related to the polymerizing effect of angiogenin on actin.
Two widely distributed multifunctional growth factors, bFGF and TNF-a, are angiogenic molecules with distinct cellular receptors for different cellular responses. Stimulation of angiogenesis induced by these molecules in vivo is thought to occur via binding to these receptors, which have been identified from cells in culture. The fact that both bFGF and TNF-a can bind to actin suggests that this may reflect a more general mechanism induced by different angiogenic molecules and perhaps provide a common pathway of angiogenesis. Indeed the ubiquitous distribution of actin may provide a convenient and effective way to regulate angiogenesis. Moreover, the inhibitory activity of actin on angiogenesis induced by angiogenin in the CAM suggests a class of angiogenesis inhibitors that may have therapeutic benefit in pathological conditions characterized by excessive blood vessel growth.
